Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 5, 2003, Pages 564-570

  Riddle, Tara M ^a   Fichtenbaum, Carl J ^a   Hui, David Y ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Lipoproteins; Liver steatosis; Ritonavir; Sterol regulatory element binding protein

Indexed keywords

CHOLESTEROL; POLYUNSATURATED FATTY ACID; PROTEINASE INHIBITOR; RECOMBINANT LEPTIN; RITONAVIR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; DIET THERAPY; DRUG EFFECT; DYSLIPIDEMIA; FATTY LIVER; LIPID STORAGE; LIPODYSTROPHY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ANIMALS; AZO COMPOUNDS; CCAAT-ENHANCER-BINDING PROTEINS; CHOLESTEROL; COLORING AGENTS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FAT NECROSIS; FATTY ACIDS, UNSATURATED; HIV PROTEASE INHIBITORS; HYPERLIPIDEMIAS; LEPTIN; LIPID METABOLISM; LIPIDS; LIPODYSTROPHY; LIVER; MALE; MICE; MICE, INBRED C57BL; ORGAN SIZE; RITONAVIR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0042627770     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200308150-00003     Document Type: Article

References (24)

1. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493-2505.
2. Hruz PW, Murata H, Mueckler M. Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. Am J Physiol. 2001;280:E549-E553.
3. Sutinen J, Hakkinen A-M, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS. 2002;16:2183-2193.
4. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15:F11-F18.
5. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999;100:700-705.
6. Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem. 2001;276: 37514-37519.
7. Nguyen AT, Gagnon AM, Angel JB, et al. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS. 2000;14:2467-2473.
8. Shimano H, Horton JD, Hammer RE, et al. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest. 1996;98:1575-1584.
9. Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 1998;12:3182-3194.
10. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 1999;274:30028-30032.
11. Xu J, Teran-Garcia M, Park JHY, et al. Polyunsaturated fatty acids suppress hepatic sterol regulatory element binding protein-1 expression by accelerating transcript decay. J Biol Chem. 2001;276: 9800-9807.
12. Worgall TS, Sturley SL, Seo T, et al. Polyunsaturated fatty acids decrease expression of promoters with sterol regulatory elements by decreasing levels of mature sterol regulatory element binding protein. J Biol Chem. 1998;273:25537-25540.
13. Worgall TS, Johnson RA, Seo T, et al. Unsaturated fatty acid mediated decreases in sterol regulatory element-mediated gene transcription are linked to cellular sphingolipid metabolism. J Biol Chem. 2002;277:3878-3885.
14. Ou J, Tu H, Shan B, et al. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci U S A. 2001;98:6027-6032.
15. Kim JB, Sarraf P, Wright M, et al. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADDI/SREBP1. J Clin Invest. 1998;101:1-9.
16. Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401:73-76.
17. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346:570-578.
18. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109:1345-1350.
19. Riddle TM, Schildmeyer NM, Phan C, et al. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res. 2002;43:1458-1463.
20. Cohen P, Miyazaki M, Socci ND. et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science. 2002;297: 240-243.
21. Yarasheski KE, Zachwieja JJ, Horgan MM, et al. Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metabolism. 1997;46:303-305.
22. Ballinger A, Kelly PEH, Besser R, et al. Plasma leptin in chronic inflammatory bowel disease and HIV: implications for the pathogenesis of anorexia and weight loss. Clin Sci (London). 1998;94: 479-483.
23. Christeff N, Melchior JC, de Truchis P, et al. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidemia and steroid hormone alterations. AIDS. 1999;13:2251-2260.
24. Estrada V, Serrano-Rios M, Larrad MTM, et al. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:32-40.